Loading data for FBLG — first visit, this takes a few seconds.
FibroBiologics, Inc. (FBLG)
NasdaqCM: FBLG
· Real-Time Price · USD
1.44
-0.05 (-3.36%)
At close: Sep 01, 2026, 8:00 PM
The price, the headline numbers and the latest news, in one place.
FibroBiologics, Inc. (FBLG) Stock Price, Analysis & Data
No data available
| Bid | 1 |
| Market Cap | 14M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -18.1M |
| 1.22 | |
| -5.1 | |
| n/a | |
| -0.65 | |
| P/B (ttm) | 2.77 |
| P/S (ttm) | 0.00 |
| Earnings Date | Aug 14, 2025 |
| Ask | 1.46 |
| Volume | 143,715 |
| Avg. Volume (20D) | 178,811 |
| Open | 1.50 |
| Previous Close | 1.49 |
| Day's Range | 1.42 - 1.54 |
| 52-Week Range | 0.62 - 12.56 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About FBLG
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease;...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 31, 2024
Employees 15
Stock Exchange NasdaqCM
Ticker Symbol FBLG
Website https://fibrobiologics.com
Financial Performance
In 2025, FibroBiologics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -18.65M, an increase of 67.06%.
Financial StatementsEarnings Surprise
FibroBiologics has released their quarterly earnings on Jul 31, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.66 exceeds estimates by 0.27, with 72.50% YoY growth.
FibroBiologics, Inc. is scheduled to release its earnings on Aug 14, 2025, after market closes.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
